Cargando…
The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study
BACKGROUND: Pharmacist medication review has been implemented in many health organizations throughout the world in an attempt to alleviate the underlying risk of polypharmacy in elderly patients. These consultations are often frequent and prolonged, and are thus associated with increased costs. To d...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896278/ https://www.ncbi.nlm.nih.gov/pubmed/35241170 http://dx.doi.org/10.1186/s13584-022-00513-0 |
_version_ | 1784663128393383936 |
---|---|
author | Harmatz, Danielle Vinker, Shlomo Wagner, Talia Raveh, Tal Merzon, Eugene Cohen, Avivit Golan |
author_facet | Harmatz, Danielle Vinker, Shlomo Wagner, Talia Raveh, Tal Merzon, Eugene Cohen, Avivit Golan |
author_sort | Harmatz, Danielle |
collection | PubMed |
description | BACKGROUND: Pharmacist medication review has been implemented in many health organizations throughout the world in an attempt to alleviate the underlying risk of polypharmacy in elderly patients. These consultations are often frequent and prolonged, and are thus associated with increased costs. To date, data regarding the most effective way to utilize pharmacist consultations for the improvement of health status is scant. AIM: To evaluate the effectiveness of a single pharmacist consultation on changes in chronic medication regimes and on selected outcomes of diabetes 1-year after the consultation. METHODS: A case–control study included an intervention group of 740 patients who had pharmacist consultations and a reference group of 1476 matched patients who did not have a pharmacist consultation. 1-year outcome measures were compared including changes in medications, improved safety, and objective variables such as Hba1c, blood pressure, and lipid profile. RESULTS: In the pharmacist consultation group, there were significantly more treatment changes ([mean 1.5 vs. 0.7, p < 0.001 medications were stopped], and [mean 1.3 vs. 0.4, p < 0.05 medications were started]). Patient safety improved with a general reduction in opiates and benzodiazepines ([50.0% vs. 31.6%, p < 0.05 opioids were stopped] and [58.8% vs 43.8%, p < 0.001 benzodiazepines were stopped]). Sulfonylurea treatment reduced (10.7% vs. 3.6%, p < 0.05 patients who stopped Sulfonylurea) and Glucagon-like peptide-1 receptor agonists (GLP-1) increased (16.4% vs. 11.2%, p < 0.001 patients who started GLP-1). Additionally, HbA1c levels showed a small decrease in the pharmacist consultation group ([− 0.18 ± 1.11] vs. [− 0.051 ± 0.80], p = 0.0058) but no significant differences were found regarding blood pressure or lipids profile. CONCLUSION: A single pharmacist consultation beneficially impacted specific clinical and patient safety outcomes. Pharmacist consultations may thus help resolve polypharmacy complexities in primary care. |
format | Online Article Text |
id | pubmed-8896278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88962782022-03-14 The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study Harmatz, Danielle Vinker, Shlomo Wagner, Talia Raveh, Tal Merzon, Eugene Cohen, Avivit Golan Isr J Health Policy Res Original Research Article BACKGROUND: Pharmacist medication review has been implemented in many health organizations throughout the world in an attempt to alleviate the underlying risk of polypharmacy in elderly patients. These consultations are often frequent and prolonged, and are thus associated with increased costs. To date, data regarding the most effective way to utilize pharmacist consultations for the improvement of health status is scant. AIM: To evaluate the effectiveness of a single pharmacist consultation on changes in chronic medication regimes and on selected outcomes of diabetes 1-year after the consultation. METHODS: A case–control study included an intervention group of 740 patients who had pharmacist consultations and a reference group of 1476 matched patients who did not have a pharmacist consultation. 1-year outcome measures were compared including changes in medications, improved safety, and objective variables such as Hba1c, blood pressure, and lipid profile. RESULTS: In the pharmacist consultation group, there were significantly more treatment changes ([mean 1.5 vs. 0.7, p < 0.001 medications were stopped], and [mean 1.3 vs. 0.4, p < 0.05 medications were started]). Patient safety improved with a general reduction in opiates and benzodiazepines ([50.0% vs. 31.6%, p < 0.05 opioids were stopped] and [58.8% vs 43.8%, p < 0.001 benzodiazepines were stopped]). Sulfonylurea treatment reduced (10.7% vs. 3.6%, p < 0.05 patients who stopped Sulfonylurea) and Glucagon-like peptide-1 receptor agonists (GLP-1) increased (16.4% vs. 11.2%, p < 0.001 patients who started GLP-1). Additionally, HbA1c levels showed a small decrease in the pharmacist consultation group ([− 0.18 ± 1.11] vs. [− 0.051 ± 0.80], p = 0.0058) but no significant differences were found regarding blood pressure or lipids profile. CONCLUSION: A single pharmacist consultation beneficially impacted specific clinical and patient safety outcomes. Pharmacist consultations may thus help resolve polypharmacy complexities in primary care. BioMed Central 2022-03-03 /pmc/articles/PMC8896278/ /pubmed/35241170 http://dx.doi.org/10.1186/s13584-022-00513-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Original Research Article Harmatz, Danielle Vinker, Shlomo Wagner, Talia Raveh, Tal Merzon, Eugene Cohen, Avivit Golan The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study |
title | The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study |
title_full | The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study |
title_fullStr | The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study |
title_full_unstemmed | The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study |
title_short | The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study |
title_sort | efficacy of single pharmacist medication review among type ii diabetic patients who take six chronic medications or more: a case–control study |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896278/ https://www.ncbi.nlm.nih.gov/pubmed/35241170 http://dx.doi.org/10.1186/s13584-022-00513-0 |
work_keys_str_mv | AT harmatzdanielle theefficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy AT vinkershlomo theefficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy AT wagnertalia theefficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy AT ravehtal theefficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy AT merzoneugene theefficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy AT cohenavivitgolan theefficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy AT harmatzdanielle efficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy AT vinkershlomo efficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy AT wagnertalia efficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy AT ravehtal efficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy AT merzoneugene efficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy AT cohenavivitgolan efficacyofsinglepharmacistmedicationreviewamongtypeiidiabeticpatientswhotakesixchronicmedicationsormoreacasecontrolstudy |